troglitazone has been researched along with Atypical Lipomatous Tumor in 4 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JH | 1 |
| Enloe, BM | 1 |
| Weybright, P | 1 |
| Campbell, N | 2 |
| Dorfman, D | 1 |
| Fletcher, CD | 3 |
| Cory, DG | 1 |
| Singer, S | 3 |
| Nikolaidis, P | 1 |
| Silverman, SG | 1 |
| Cibas, ES | 1 |
| Vansonnenberg, E | 1 |
| Rybicki, FJ | 1 |
| Manola, JB | 1 |
| Tuncali, K | 1 |
| Karshbaum, SH | 1 |
| Demetri, GD | 2 |
| Mueller, E | 1 |
| Sarraf, P | 1 |
| Naujoks, R | 1 |
| Spiegelman, BM | 1 |
| Goss, G | 1 |
| Demetri, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma[NCT00003058] | Phase 2 | 85 participants (Actual) | Interventional | 1997-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for troglitazone and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
Topics: Chromans; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Liposarcoma; Male; | 2000 |
1 trial available for troglitazone and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.
Topics: Adult; Biopsy; Cell Differentiation; Chromans; DNA-Binding Proteins; Female; Gene Expression Regulat | 1999 |
2 other studies available for troglitazone and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy.
Topics: 3T3 Cells; Adipocytes; Animals; Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Chroma | 2002 |
Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy.
Topics: Adult; Antineoplastic Agents; Biopsy, Needle; Chromans; Clinical Trials, Phase II as Topic; Feasibil | 2005 |